MDxHealth SA (MDXH)
After hours:
- GlobeNewswire
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 millionIncreasing 2024 revenue guidance to $83-85 million, previously $79-81 million Conference call with Q&A today at 08:30 AM ET / 14:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 1, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the first qu
- Globe Newswire
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel. With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient’s risk
- Insider Monkey
MDxHealth SA (NASDAQ:MDXH) Q4 2023 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH) Q4 2023 Earnings Call Transcript March 6, 2024 MDxHealth SA misses on earnings expectations. Reported EPS is $-0.39 EPS, expectations were $-0.28. MDXH isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and gentlemen and […]
